ArticleBMC urology2025
NPRL2 gene expression as a predictor of biochemical recurrence after robot-assisted radical prostatectomy.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the potential prognostic role of nitrogen permease regulator-like 2 (NPRL2) gene expression in predicting biochemical recurrence (BCR) following robot-assisted radical prostatectomy (RARP). MATERIALS AND
methodsThis single-center retrospective study included patients who underwent RARP performed by three different surgeons. Clinicopathological data and NPRL2 expression in tumor tissues were evaluated immunohistochemically (IHC). The level of NPRL2 staining was quantitatively assessed using an IHC score based on staining intensity. Factors associated with BCR were analyzed using multivariable logistic regression.
resultsA preoperative PSA level > 10 ng/mL (OR: 4.10, 95% CI: 1.38-12.20, p = 0.011), an International Society of Urological Pathology (ISUP) grade group > 3 (OR: 4.39, 95% CI: 1.45-13.29, p = 0.009), and high NPRL2 expression (IHC score > 4) (OR: 3.82, 95% CI: 1.07-13.62, p = 0.039) were identified as independent risk factors for BCR.
conclusionHigh NPRL2 expression is associated with an increased risk of BCR following RARP. These findings suggest a potential prognostic value of NPRL2; however, further validation studies are needed due to the small sample size and the subjective nature of the assessment. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.